These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22844687)

  • 1. Lenalidomide: second cancers.
    Prescrire Int; 2012 May; 21(127):130. PubMed ID: 22844687
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
    Mariz JM; Esteves GV
    Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide, a thalidomide derivative, shows promise in various applications.
    Oestreicher P
    ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
    [No Abstract]   [Full Text] [Related]  

  • 5. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
    Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M; Jakubowiak A; Mehta J; Niesvizky R; Orlowski R; Siegel D; Singhal S; Vescio R; Wang M; Zangari M; Munshi NC
    Clin Adv Hematol Oncol; 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PubMed ID: 18000495
    [No Abstract]   [Full Text] [Related]  

  • 6. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
    Bonkowski J; Vermeulen LC; Kolesar JM
    J Oncol Pharm Pract; 2010 Dec; 16(4):223-32. PubMed ID: 19910392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide in multiple myeloma: Current status and future potential.
    Quach H; Kalff A; Spencer A
    Am J Hematol; 2012 Dec; 87(12):1089-95. PubMed ID: 22641420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide and lenalidomide: overview of the French pharmacovigilance database.
    Prescrire Int; 2012 Mar; 21(125):72. PubMed ID: 22428194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
    Dasanu CA; Alexandrescu DT
    Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide in multiple myeloma.
    Sirohi B; Powles R
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1559-70. PubMed ID: 19895240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
    Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
    Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
    Tannemaat MR; Vries EP; Molendijk WJ; Haan J
    Clin Neurol Neurosurg; 2011 Jul; 113(6):488-9. PubMed ID: 21315504
    [No Abstract]   [Full Text] [Related]  

  • 15. Lenalidomide in multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.
    Rifkin RM; Abonour R; Shah JJ; Mehta J; Narang M; Terebelo H; Gasparetto C; Toomey K; Hardin JW; Lu JJ; Kenvin L; Srinivasan S; Knight R; Nagarwala Y; Durie BG
    Leuk Lymphoma; 2016 Sep; 57(9):2228-31. PubMed ID: 26766599
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of thalidomide in multiple myeloma.
    Schwab C; Jagannath S
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):26-9. PubMed ID: 16879766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
    Seki JT; Banglawala S; Lentz EM; Reece DE
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
    [No Abstract]   [Full Text] [Related]  

  • 19. [Lenalidomide. Treatment of multiple myeloma].
    Musch A
    Med Monatsschr Pharm; 2008 Jan; 31(1):4-8; quiz 9-10. PubMed ID: 18522014
    [No Abstract]   [Full Text] [Related]  

  • 20. Lenalidomide and second malignancies in myeloma patients.
    Pratt G
    Lancet Oncol; 2014 Mar; 15(3):253-4. PubMed ID: 24525201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.